Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06134232 · ClinicalTrials.gov registry record · Phase 2
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Dendreon.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06134232: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Dendreon.
NCT06134232 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Dendreon. The registered enrollment target is 400 participants, roughly in line with the 387-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06134232, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Dendreon.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Primary Outcome
To assess the humoral response ((i.e. antibody titer) to PAP and PA2024 after booster infusion in subjects with metastatic castrate-resistant prostate cancer who have received a single booster dose of sipuleucel-T vs those subjects who have not
Conditions Studied
Interventions
- DRUG Sipuleucel-T Injection
Study Locations (20)
Florida
- Advanced Urology Institute - Daytona Beach
- Advanced Urology Institute - Largo
- Advanced Urology Institute - Ocala
- Florida Urology Partners - Riverview
California
- City of Hope - National Medical Center - Duarte
- Urology Associates of Central California Medical Group - Fresno
- Unio Health Partners - Genesis Research, LLC - San Diego
Illinois
- Associated Urological Specialists - Chicago Ridge
- UroPartners - Glenview
- Advanced Urology Associates - New Lenox
Indiana
- Urology of Indiana - Carmel
- First Urology - Jeffersonville
- Urologic Specialists of Northwest Indiana - Merrillville
New York
- Integrated Medical Professionals - North Hills
- Associated Medical Professionals of NY - Syracuse
Arizona
- Arizona Urology Specialists - Tuscon
Colorado
- Colorado Urology - Lakewood
Maryland
- Chesapeake Urology Research Associates - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 2 |
What NCT06134232 shows while recruiting
NCT06134232 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 387-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which Sipuleucel-T Injection is the first listed.
NCT06134232 names 20 study sites across 10 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06134232 about?
NCT06134232 is a clinical study titled "Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T". A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
What is the current status of trial NCT06134232?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2023-10-02. Estimated completion is 2032-06-30.
What conditions does trial NCT06134232 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT06134232?
The interventions under investigation include: Sipuleucel-T Injection (DRUG).
Who is sponsoring clinical trial NCT06134232?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06134232 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06134232's enrollment target sits among peer trials
400 7th of 15 higher than 9 of 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
RECRUITING · Phase 2
-
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
ACTIVE NOT RECRUITING · Phase 2
-
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
RECRUITING · Phase 1
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI